Leap Therapeutics Completes $58.88 Million Cash Private Placement Led by Winklevoss Capital

biotechnology company Leap Therapeutics (NASDAQ stock code: LPTX) announced today that it has completed the previously announced private placement led by Winklevoss Capital, raising $58,888,888 in cash to launch its digital asset financial strategy. Winklevoss Capital will provide funding and strategic support to help Leap build and execute its digital asset financial strategy. Under the lead investor agreement, the Leap board of directors will increase to 12 members, Winklevoss Capital will have the right to nominate two individuals to the Leap board of directors, one of whom will also serve as chairman of the board. Morgan, Lewis & Bockius LLP serves as Leap's legal counsel, and Cooley LLP serves as Winklevoss Capital's legal counsel.